 |
 Video: What is a Stock Split?
|
|
|
| Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Co.'s clinical-stage product candidates include: Seralutinib, also known as GB002, which is an inhaled small molecule, platelet-derived growth factor receptor colony-stimulating factor 1 receptor and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, which is an oral small molecule for the treatment of inflammatory bowel disease; and GB5121, which an oral small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma. According to our Gossamer Bio stock split history records, Gossamer Bio has had 0 splits. | |
|
Gossamer Bio (GOSS) has 0 splits in our Gossamer Bio stock split history database.
Looking at the Gossamer Bio stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Gossamer Bio shares, starting with a $10,000 purchase of GOSS, presented on a split-history-adjusted basis factoring in the complete Gossamer Bio stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
02/11/2019 |
|
| End date: |
05/02/2024 |
|
| Start price/share: |
$18.36 |
|
| End price/share: |
$0.77 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-95.80% |
|
| Average Annual Total Return: |
-45.51% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$419.82 |
|
| Years: |
5.22 |
|
|
|
|
|
